BIRMINGHAM, Ala., March 6, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.
Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will participate in a fireside chat on Wednesday, March 15, 2023, from 9:00 - 9:25 a.m. ET.
The presentation will be webcast live and available at http://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact:
Casey Winger| 205.970.5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
Mark Miller | 205.970.5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$100.23 |
Daily Change: | -1.11 -1.10 |
Daily Volume: | 776,330 |
Market Cap: | US$10.090B |
November 04, 2024 October 28, 2024 August 05, 2024 July 30, 2024 July 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB